Literature DB >> 21086721

Optimized conditions for high-level expression and purification of recombinant human interleukin-2 in E. coli.

Paromita Sengupta1, Kalpana Meena, Rama Mukherjee, S K Jain, Kapil Maithal.   

Abstract

Interleukin-2 (IL-2), a potent cytokine has been used in anti-cancer therapy for over a decade now. IL-2, originally identified as a growth factor for T lymphocytes is a 15 kDa hydrophobic glycoprotein that induces the activation, clonal proliferation and differentiation of T and B-lymphocytes and enhances the cytotoxicity of monocytes and natural killer (NK) cells. Here, we report a simple method for the cloning, high-level expression and purification of IL-2 protein, which can be easily extended to other bioactive therapeutic proteins. The IL-2 gene was amplified from human spleen cDNA and cloned in a prokaryotic (E. coli) expression system. An optimal expression of the IL-2 protein was determined by varying the expression conditions like temperature, inducer concentration and duration of induction. The protein was expressed as inclusion bodies and a panel of reagents including detergents, urea and guanidine hydrochloride were used to solubilize it. After solubilization, the protein was renatured and subjected to a single step gel-filtration chromatography to yield immunobioactive IL-2 protein with > 99% purity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 21086721

Source DB:  PubMed          Journal:  Indian J Biochem Biophys        ISSN: 0301-1208            Impact factor:   1.918


  3 in total

1.  Optimized condition for enhanced soluble-expression of recombinant mutant anabaena variabilis phenylalanine ammonia lyase.

Authors:  Hossein Zarei Jaliani; Safar Farajnia; Yaghoub Safdari; Seyyed Abolghasem Mohammadi; Abolfazl Barzegar; Saeed Talebi
Journal:  Adv Pharm Bull       Date:  2014-02-07

2.  Purification and Conformational Characterization of a Novel Interleukin-2 Mutein.

Authors:  Leina Moro-Pérez; Sum Lai Lozada-Chang; Gabriela Rivas-García; Carlos Álvarez; Laritza Rojas-Pérez; Tammy Boggiano-Ayo; Yamile González-González
Journal:  Protein J       Date:  2021-10-13       Impact factor: 2.371

3.  In vitro cytotoxic effect of Trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells.

Authors:  Amir Asgari; Sedigheh Sharifzadeh; Abbas Ghaderi; Ahmad Hosseini; Amin Ramezani
Journal:  Mol Biol Rep       Date:  2019-09-06       Impact factor: 2.316

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.